Béla Péter Merkely
Inserm
4 papers in the Anchorcite directory, published between 2019 and 2021, cited 28,758 times in total.
ORCID profileResearch topics
- Diabetes Treatment and Management · 3 papers
- Heart Failure Treatment and Management · 3 papers
- Cardiovascular Function and Risk Factors · 2 papers
- Acute Ischemic Stroke Management · 1 paper
- Atrial Fibrillation Management and Outcomes · 1 paper
- Cardiac Arrhythmias and Treatments · 1 paper
Frequent co-authors
- Piotr P. Ponikowski · 3 papers
- Michael Böhm · 3 papers
- Vijay Chopra · 3 papers
- Subodh Verma · 3 papers
- Milton Packer · 2 papers
- Stefan D. Anker · 2 papers
- Javed Butler · 2 papers
- Gerasimos S Filippatos · 2 papers
Papers
- 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)European Heart Journal · 2020 · 10,550 citations
Atrial fibrillation (AF) poses significant burden to patients, physicians, and healthcare systems globally. Substantial research efforts and resources are being directed towards gaining detailed information about the mechanisms underlying AF, its natural course and effective treatments (see also the ESC…
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine · 2019 · 7,529 citations
BACKGROUND: In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with…
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureNew England Journal of Medicine · 2020 · 5,468 citations
BACKGROUNDSodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes.More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart…
- Empagliflozin in Heart Failure with a Preserved Ejection FractionNew England Journal of Medicine · 2021 · 5,211 citations
BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In…
Metadata from OpenAlex (CC0).